SUPRAX Drug Patent Profile
✉ Email this page to a colleague
When do Suprax patents expire, and when can generic versions of Suprax launch?
Suprax is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms. and is included in eight NDAs. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has two patent family members in two countries.
The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the cefixime profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Suprax
A generic version of SUPRAX was approved as cefixime by AUROBINDO PHARMA LTD on April 14th, 2015.
Summary for SUPRAX
| International Patents: | 2 |
| US Patents: | 1 |
| Applicants: | 3 |
| NDAs: | 8 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 40 |
| Clinical Trials: | 5 |
| Patent Applications: | 5,339 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SUPRAX |
| What excipients (inactive ingredients) are in SUPRAX? | SUPRAX excipients list |
| DailyMed Link: | SUPRAX at DailyMed |
Recent Clinical Trials for SUPRAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| PT Bernofarm | N/A |
| PT Pharma Metric Labs | N/A |
| AIDS Healthcare Foundation | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for SUPRAX
US Patents and Regulatory Information for SUPRAX
SUPRAX is protected by one US patents.
Patents protecting SUPRAX
Pharmaceutical compositions of cefixime
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHODS FOR TREATING BACTERIAL INFECTIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lupin Ltd | SUPRAX | cefixime | CAPSULE;ORAL | 203195-001 | Jun 1, 2012 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Lupin Ltd | SUPRAX | cefixime | TABLET, CHEWABLE;ORAL | 065380-002 | Oct 25, 2010 | RX | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Lupin Pharms | SUPRAX | cefixime | FOR SUSPENSION;ORAL | 065129-001 | Feb 23, 2004 | DISCN | No | No | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SUPRAX
See the table below for patents covering SUPRAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 112007000920 | See Plans and Pricing | |
| World Intellectual Property Organization (WIPO) | 2007119249 | See Plans and Pricing | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2022 - 2023
NCE-1 Patent Challenge Dates 2022 - 2023
ClinicalTrialExchange - Connecting volunteers and trials
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2022, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
